Major owner of Corvus Pharmaceuticals, Inc. just picked up 657,344 shares

Peter A. Thompson, a major owner of Corvus Pharmaceuticals, Inc. and a director of the company, recently acquired 657,344 shares of the company. The buys took place at prices ranging from $3.34 to $3.91 per share, on dates ranging from June 27 to July 01, 2019. Thompson now owns 6,624,928 shares of the company. Thompson operates out of Burlingame, CA. Some additional info was provided as follows:


These shares of the Issuer's common stock ("Shares") were purchased in a block order at a price of $3.34.
These Shares were purchased in a block order at a price of $3.72.
These Shares were purchased in a block order at a price of $3.91.
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the so le general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors.
Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback